Shockwave Receives FDA Breakthrough Device Designation for the Investigational Coronary IVL System
IVL-Facilitated Transfemoral TAVR
Study Now Published
MINIMIZE TRAUMA – Minimize trauma to soft tissue by safely selecting and fracturing intimal and medial calcium
OPTIMIZE OUTCOMES – Optimize outcomes while reducing complications and cost escalation
SIMPLIFY PROCEDURES – Simple and intuitive system that makes complex calcified procedures more predictable
The First Applications of
Learn more about the potential of IVL in patients with aortic stenosis (AS) or IVL as a means to facilitate transfemoral access and avoid alternative routes by clicking on one of the below:
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
A comprehensive review by Dr. Andrew Holden at #VEITH2019 on the #ShockwaveIVL DISRUPT PAD III observational arm sh… https://t.co/RUM2Lyodc1
Excellent presentation by #IVL expert Dr @RAAnderson1 at London Valves #PCRLV on the successful delivery & implanta… https://t.co/4iRNkIuSiV
Planning your next few days in NYC for #VEITH2019? We’ve pulled together a list of our #ShockwaveIVL events that we… https://t.co/q3506bWWym
Opa! Great presentation by Dr. Pilatis on Calcified Lesions, highlighting #ShockwaveIVL, during the Interventional… https://t.co/ZLXUk5OP7i
1st Pre-TAVI #ShockwaveIVL case in Greece! Congratulations, Dr. George Karavolias, Dr Georgia Karabela & team at Me… https://t.co/2vfbKYwjaV
Blimey, we were blown away by the attendance at our #PCRLV session! Thank you all for attending to learn more about… https://t.co/hy0CsJWuIj
Queue up the live stream! Our #ShockwaveIVL session at PCR London Valves #PCRLV begins in 1 hour! Tune in to learn… https://t.co/iBnO85FTwS
Attending #VEITH2019 in a few days? Grab a seat in our Thursday symposia or visit our booth to learn more about our… https://t.co/oWyKeubgnA
Familiar with the challenges of transfemoral access? Attend our session at PCR London Valves #PCRLV to discover how… https://t.co/3LxI2oNku7
Can’t make it to PCR London Valves #PCRLV next week? You can live stream our #ShockwaveIVL session, A New Alternati… https://t.co/3cjEDQlFfX
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
